CRIS Current Research Information System

DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.382
NA - Nord America 2.707
EU - Europa 1.482
SA - Sud America 221
Continente sconosciuto - Info sul continente non disponibili 198
AF - Africa 154
OC - Oceania 9
Totale 9.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.610
VN - Vietnam 1.177
SG - Singapore 1.155
CN - Cina 869
HK - Hong Kong 508
IT - Italia 419
DE - Germania 325
BD - Bangladesh 242
BR - Brasile 155
KR - Corea 136
FR - Francia 124
NL - Olanda 122
SE - Svezia 122
FI - Finlandia 78
GB - Regno Unito 76
IN - India 76
JP - Giappone 53
CA - Canada 50
CI - Costa d'Avorio 46
IE - Irlanda 44
SC - Seychelles 40
RU - Federazione Russa 38
PH - Filippine 34
ID - Indonesia 30
PL - Polonia 22
TH - Thailandia 22
AR - Argentina 21
MX - Messico 20
TG - Togo 18
AT - Austria 17
BG - Bulgaria 17
BE - Belgio 16
CO - Colombia 15
ES - Italia 12
GH - Ghana 12
TW - Taiwan 11
ZA - Sudafrica 11
IQ - Iraq 10
TR - Turchia 10
AU - Australia 9
CH - Svizzera 9
CL - Cile 8
EC - Ecuador 8
JO - Giordania 8
VE - Venezuela 8
GR - Grecia 7
JM - Giamaica 7
UA - Ucraina 7
LT - Lituania 6
PK - Pakistan 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
CZ - Repubblica Ceca 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
NP - Nepal 4
SA - Arabia Saudita 4
TN - Tunisia 4
AL - Albania 3
EG - Egitto 3
HN - Honduras 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GT - Guatemala 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MU - Mauritius 2
NG - Nigeria 2
PT - Portogallo 2
SN - Senegal 2
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DZ - Algeria 1
HU - Ungheria 1
KW - Kuwait 1
LU - Lussemburgo 1
LY - Libia 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
OM - Oman 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 8.953
Salva come PNG Salva come JPEG
Città #
Singapore 867
Hong Kong 454
San Jose 434
Ashburn 324
Ho Chi Minh City 316
Hanoi 312
Hefei 299
Santa Clara 169
Los Angeles 159
Seoul 128
Council Bluffs 112
Chandler 96
Beijing 91
New York 86
Boardman 74
Bologna 70
Da Nang 59
Lauterbourg 58
Buffalo 57
Helsinki 53
Dallas 49
Abidjan 46
Dublin 43
Haiphong 42
Krefeld 41
Southend 37
Tokyo 37
Rome 36
Munich 33
Amsterdam 31
Frankfurt am Main 31
Milan 31
São Paulo 31
Princeton 28
Bengaluru 27
Fairfield 27
Falkenstein 26
Chicago 23
Shanghai 23
Lappeenranta 22
Jakarta 19
Lomé 18
Redondo Beach 18
Seattle 18
Houston 17
Nuremberg 17
Sofia 17
Guangzhou 16
Hải Dương 16
Bad Bellingen 15
San Francisco 14
Shenzhen 14
Toronto 14
Turin 14
Brussels 13
Warsaw 13
Brooklyn 12
Des Moines 12
Naples 12
Wilmington 12
Accra 11
Cambridge 11
London 11
San Diego 11
Woodbridge 11
Atlanta 10
Bangkok 10
Berlin 10
Düsseldorf 10
Mexico City 10
Denver 9
Genoa 9
Montreal 9
Ninh Bình 9
Orem 9
Rio de Janeiro 9
Thái Nguyên 9
Tongling 9
Amman 8
Bắc Ninh 8
Can Tho 8
Biên Hòa 7
Bắc Giang 7
Fort Worth 7
Ha Long 7
Hangzhou 7
Nha Trang 7
Phoenix 7
Stockholm 7
Trento 7
Ann Arbor 6
Bexley 6
Bến Tre 6
Florence 6
Hillsboro 6
Monzuno 6
Moscow 6
Nanjing 6
Quận Bình Thạnh 6
Điện Bàn 6
Totale 5.507
Salva come PNG Salva come JPEG
Nome #
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 415
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 284
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 216
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 202
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 194
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 187
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 183
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 176
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 175
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 175
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 173
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 162
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome 161
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 159
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 157
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 155
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 154
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 149
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 147
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. 139
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 128
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 127
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 126
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 122
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 115
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 114
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 112
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 108
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 107
CAR-T cell therapy: A potential new strategy against prostate cancer 105
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 105
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 102
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 100
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 100
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 97
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 96
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 93
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 92
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 92
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 92
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 91
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 91
New prognostic biomarkers in metastatic castration-resistant prostate cancer 91
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 90
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 87
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial 86
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 86
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 85
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 85
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 85
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 85
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 82
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 82
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 80
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 78
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 78
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 77
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 76
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 75
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 71
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 70
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 67
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 66
Immunotherapy for prostate cancer: Where we are headed 66
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 64
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 62
Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3) 62
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 60
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 60
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 58
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 58
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA 56
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 55
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 54
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 54
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 52
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 52
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 49
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 43
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 42
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 39
Psychosocial issues in long-term survivors of testicular cancer 39
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 35
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 35
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 29
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 25
Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404](S1040842824001471)(10.1016/j.critrevonc.2024.104404) 22
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 19
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 18
Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors 18
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 16
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 11
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors 10
null 2
Totale 9.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.876
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022230 0 0 3 6 9 4 25 16 5 50 74 38
2022/2023343 20 48 11 47 22 44 8 16 72 9 20 26
2023/2024364 10 17 5 3 9 39 15 15 204 21 17 9
2024/20251.699 100 207 121 152 230 108 52 68 17 138 101 405
2025/20265.877 357 423 386 363 452 117 1.238 347 1.044 458 383 309
2026/2027501 218 283 0 0 0 0 0 0 0 0 0 0
Totale 9.153